#HVO hVIVO PLC – Positive data from novel human challenge models November 11, 2025 – Posted in: hVIVO (HVO) – Tags: clinical, conference, european, HVO, influenza, scientific, trial, valencia
hVIVO plc (AIM: HVO), a full-service early phase Contract Research Organisation (CRO) and the world leader in human challenge clinical trials, announces key insights from its scientific presentations at the 10th European Scientific Working Group on Influenza (“ESWI”) Conference in Valencia, and the World Vaccine Congress Europe in Amsterdam, which both took place in October 2025.
hVIVO presented positive data from a number of newly developed human challenge models reinforcing hVIVO’s continued world-leading capabilities in accelerating the development of novel challenge agents and its readiness to meet customer demand for innovative and effective clinical trial solutions.
Human Metapneumovirus (“hMPV”) challenge model
hVIVO’s Senior Study Physician, Dr Alexander Lima, presented the positive findings from the newly developed, and world’s only contemporary-strain hMPV human challenge model. The presentation at ESWI, titled, “Disease characteristics and immunological profiles obtained from newly developed hMPV human challenge model“, highlighted the model’s strong performance using a recent 2a strain, which compared favourably against hVIVO’s established RSV A model, a benchmark for model performance for this particular virus family. The model demonstrated high infection and symptomatic disease attack rates and robust AUC virology by qRT-PCR, and is now ready and available for vaccine and antiviral human challenge trials.
SARS-CoV-2 Omicron challenge model
Alex Mann, Senior Director Clinical Science presented, “Development of a SARS-CoV-2 Omicron BA5 human challenge model” at ESWI. This presentation highlighted the success of hVIVO’s Omicron human challenge model which performs favourably in seropositive, previously vaccinated participants and confirmed the model’s suitability for use in vaccine and treatment studies. A key insight from the presentation was the importance of timing of dosing post-inoculation, particularly in the context of post-exposure prophylaxis. This represents the first commercially available Omicron human challenge model.
Respiratory Syncytial Virus B (RSV B) challenge model
At the World Vaccine Congress Europe, hVIVO’s Chief Scientific Officer, Dr Andrew Catchpole showcased the positive results from hVIVO’s new RSV B model titled, “High infection rates achieved with the worlds’ first RSV B challenge models key component of our RSV-hMPV-PIV combination vaccine efficacy testing platform.” The data confirmed the robustness of the RSV B model, which is now available for vaccine and anti-viral efficacy testing. The development of the RSV B and hMPV models, along with the Company’s collecting of PIV (parainfluenza virus) clinical samples, has enabled the Company to create a comprehensive efficacy testing platform enabling the Company to test individual components of the next generation combination vaccines under development.
Any interested parties should contact bd@hvivo.com to learn more about these new models.
Dr Andrew Catchpole, Chief Scientific Officer of hVIVO, said: “We are delighted to have presented such positive data across three pathogens, hMPV, RSV B, and Omicron, at two of the industry’s most influential scientific conferences. These results not only validate our unmatched expertise in designing and delivering new challenge models but also reinforce hVIVO’s commitment to accelerating the development of vital vaccines and therapeutics and ensuring we have models that reflect industry’s evolving needs.”
For further information please contact:
| hVIVO plc | +44 (0)20 7756 1300 | |||
| Yamin ‘Mo’ Khan, Chief Executive Officer
Stephen Pinkerton, Chief Financial Officer |
||||
| Cavendish Capital Markets Limited (Nominated Adviser and Joint Broker) |
+44 (0)20 7220 0500 | |||
| Geoff Nash, Callum Davidson, Trisyia Jamaludin, Harriet Ward Nigel Birks – Life Science Specialist Sales Louise Talbot – Sales |
||||
| Peel Hunt LLP (Joint Broker) | +44 (0)20 7418 8900 | |||
| James Steel, Dr Christopher Golden | ||||
| Davy (Joint Broker) | +353 (0) 1 679 6363 | |||
| Anthony Farrell, Niall Gilchrist | ||||
| Walbrook PR (Financial PR & IR)
Paul McManus / Alice Woodings / Lianne Applegarth |
+44 (0)20 7933 8780 or hvivo@walbrookpr.com
+44 (0)7980 541 893 / +44 (0)7407 804 654/ |
|||